NEW YORK, Oct. 3 – Microarray technology developer Nanogen said Wednesday that it had sold seven of its NanoChip Molecular Biology Workstations during the quarter and placed another three through non-title transfer agreements to development site partners.
Nanogen said that it has placed 40 of its SNP scoring workstations to unnamed customers and collaborators.
Howard Birndorf, Nanogen’s founder and executive chairman, said that the company decided to make the announcement in light of the current economic downturn.
“I'm pleased to report that our title transfer transactions recorded as product revenue more than tripled over the last quarter, keeping us on track to meet our year-end placement goals and revenue forecasts," Birndorf said in a statement.
Nanogen’s microarray technology uses a matrix of 100 charged pads to immobilize strands of DNA to perform assays. It is designed to investigate SNPs, short tandem repeats, insertions, and deletions.
On Tuesday, Nanogen competitor Sequenom announced that it had sold 10 of its MassArray gene analysis systems to a variety of companies and institutions during the third quarter. Sequenom said it has sold 48 systems to date.